주요 콘텐츠로 건너뛰기

귀하의 브라우저가 완벽하게 지원되지 않습니다. 옵션이 있는 경우 최신 버전으로 업그레이드하거나 Mozilla Firefox, Microsoft Edge, Google Chrome 또는 Safari 14 이상을 사용하세요. 가능하지 않거나 지원이 필요한 경우 피드백을 보내주세요.

이 새로운 경험에 대한 귀하의 의견에 감사드립니다.의견을 말씀해 주세요

Elsevier
엘스비어와 함께 출판

Elsevier Connect에 오신 것을 환영합니다.

연구, 의료 및 기술 커뮤니티를 위한 뉴스, 정보 및 특집 기사.

Students sitting around a table at library

주목받는 이야기

The future we build could depend on research we don’t read

Policy is meant to be shaped by evidence. But what happens when the most relevant research never reaches decision-makers?

New research supported by Elsevier datasets suggests that roughly two-thirds of highly policy-relevant science may go uncited — not because it lacks quality, but because it remains invisible. As AI becomes part of how evidence is found and synthesized, trusted sources, transparency and broader visibility are becoming essential to better decisions.

What if the next life-saving drug is buried in a patent diagram?

In drug discovery, the evidence researchers need often already exists — scattered across journals, patents, figures and chemical diagrams that conventional search may miss.

AI-supported workflows grounded in trusted scientific knowledge are helping researchers connect chemistry, bioactivity and patent evidence faster, with insights traceable back to their sources. From surfacing hidden chemistry in images to exploring millions of drug–disease connections at scale, better access to quality information can help teams move from search to decision with greater confidence.